On November 20, 2026, Saidal, a leading Algerian pharmaceutical company, announced the launch of Dapaflux, a new medication designed to treat type 2 diabetes and prevent its cardiac and kidney complications. The launch event took place in Algiers, the capital city of Algeria, and was attended by senior officials from the Ministry of Pharmaceutical Industry and experts in the field. The medication is an innovative treatment that aims to improve the management of type 2 diabetes.
The launch event, titled "Convergence: A Shared Approach," was held under the supervision of Saidal's General Director, Yunes Bouaeraara. The event was also attended by Abdelhakim Boualdis, Secretary General of the Ministry of Pharmaceutical Industry, representing the Minister, Dr. Wassim Quoidri. Other attendees included the General Director of the National Agency for Pharmaceutical Materials, Sharif Dlih, and Professor Ammar Tabaibiba, head of the expert committee responsible for advising on the national list of essential medicines.
According to Saidal, Dapaflux is an innovative medication that targets the treatment of type 2 diabetes and the prevention of its cardiac and kidney complications. The medication is part of Saidal's strategy to diversify its therapeutic areas and strengthen its industrial and technological capabilities. The launch of Dapaflux is a significant milestone in Saidal's development, reflecting its commitment to providing high-quality medications at affordable prices to Algerian patients.
Abdelhakim Boualdis, representing the Minister of Pharmaceutical Industry, emphasized the importance of adopting a comprehensive approach to managing type 2 diabetes. This approach focuses on early detection, regular monitoring, and prevention of cardiac and kidney complications. Boualdis also highlighted that this initiative aligns with the strategic vision of the President of the Republic, Abdelmadjid Tebboune, to enhance healthcare sovereignty and improve the management of chronic diseases.
The launch of Dapaflux demonstrates Saidal's commitment to innovation and its goal of providing Algerian patients with access to high-quality medications. The medication is expected to play a significant role in improving the management of type 2 diabetes in Algeria. Saidal's General Director, Yunes Bouaeraara, reiterated the company's commitment to ensuring that its medications are accessible to all patients at affordable prices.
The development of Dapaflux is a significant achievement for Saidal, reflecting its capabilities in research and development. The medication is the result of collaboration between Saidal's research team and international partners. The launch of Dapaflux is expected to contribute to the growth of Algeria's pharmaceutical industry and enhance the country's healthcare sector.
The introduction of Dapaflux is a positive development for Algerian patients with type 2 diabetes. The medication offers new hope for improved management of the disease and prevention of related complications. Saidal's commitment to innovation and quality is reflected in the launch of Dapaflux, which is expected to have a positive impact on the Algerian healthcare sector.
Key points
- Saidal launches Dapaflux, a new medication for type 2 diabetes and related complications.
Reporting sources
- صيدال تطلق دواء جديدا لمرضى السكري · ennaharonline.com